Posted by Michael Wonder on 15 Nov 2021
Wegovy recommended for approval for the treatment of obesity by the European regulatory authorities
11 November 2021 - Novo Nordisk today announced that the European Medicines Agency’s CHMP has adopted a positive opinion, recommending marketing authorisation for Wegovy for chronic weight management in adults with obesity.
Wegovy is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI ≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.
